A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause

por Fraser, Graeme L., Lederman, Samuel, Waldbaum, Arthur, Kroll, Robin, Santoro, Nanette, Lee, Misun, Skillern, Laurence, Ramael, Steven
Publicado 2020

Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)

por Hoveyda, Hamid R., Fraser, Graeme L., Dutheuil, Guillaume, El Bousmaqui, Mohamed, Korac, Julien, Lenoir, François, Lapin, Alexey, Noël, Sophie
Publicado 2015

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlle...

por Santoro, Nanette, Waldbaum, Arthur, Lederman, Samuel, Kroll, Robin, Fraser, Graeme L., Lademacher, Christopher, Skillern, Laurence, Young, James, Ramael, Steven
Publicado 2020

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome

por Fraser, Graeme L, Obermayer-Pietsch, Barbara, Laven, Joop, Griesinger, Georg, Pintiaux, Axelle, Timmerman, Dirk, Fauser, Bart C J M, Lademacher, Christopher, Combalbert, Jean, Hoveyda, Hamid R, Ramael, Steven
Publicado 2021